Total Live Articles: 488

Opioid Toxicity and Overdose

Joint RCEM and NPIS best practice guideline: assessment and management of acute opioid toxicity in adults in the emergency department. Published: May 2024.

Opioid Toxicity and Overdose

Pharmacology Overview

Opioids are a drug class, not one specific drug. Common examples include: [Ref]

  • Morphine
  • Codeine
  • Fentanyl
  • Oxycodone
  • Heroin (diamorphine)

MoA: [Ref]

  • Primarily a μ (mu) opioid receptor agonist
  • μ-receptor activation causes:
    • ↓ Presynaptic Ca²⁺ influx → ↓ neurotransmitter release
    • ↑ Postsynaptic K⁺ efflux → neuronal hyperpolarisation

Key opioid related medications:

  • Acute opioid toxicity / overdose → naloxone (opioid receptor antagonist)
  • Long-term management of opioid dependence
    • Methadone = full μ-opioid receptor agonist
    • Buprenorphine = partial μ-opioid receptor agonist and κ-opioid receptor antagonist

Opiates vs opioids

  • Opiates = naturally derived from opium, e.g. morphine and codeine
  • Opioids = broader term covering natural, semi-synthetic and synthetic opioid drugs, e.g. heroin, fentanyl, methadone

Clinical Features

Classic triad of acute opioid toxicity: [RCEM/NPIS]

  • Miosis (pinpoint pupils)
  • Respiratory depression (hypoventilation and ↓ respiratory rate)
  • CNS depression (drowsiness, reduced GCS)

Other possible clinical features: [RCEM/NPIS]

  • Hypotension
  • Bradycardia
  • Hypothermia
  • Seizures
  • Other expected effects of opioids (e.g. euphoria, nausea, vomiting, pruritus)

Commonly, opioids are co-ingested with alcohol or other CNS depressants that can further exacerbate respiratory depression, such as benzodiazepines and pregabalin. [RCEM/NPIS]

Investigation and Diagnosis

Clinical diagnosis [RCEM/NPIS]

  • Urine drug screening is NOT required to diagnose acute opioid toxicity and should not delay treatment
  • Naloxone may also be used diagnostically: improvement in consciousness and respiratory depression after naloxone administration supports opioid toxicity as the cause

Acute Management

Acute opioid toxicity / overdose should be approached with an A-E assessment

  • Airway and breathing take priority (i.e. ventilation and oxygen)
  • Naloxone for suspected opioid-induced respiratory depression

Building on the A-E approach, management is based on the patient’s clinical state: [RCEM/NPIS]

  1. Respiratory rate (RR), and
  2. SpO2 on room air
Clinical state Immediate airway and breathing management Naloxone therapy
RR >10/min

AND

SpO2 >92% on RA

  • No active treatment (including naloxone) is necessary
  • Monitor RR, SpO2, ETCO2 and level of consciousness every 30 min

Consider discharge if the parameters are within normal limits for 6 hours after suspected time of overdose

RR 6-10/min

OR

SpO2 <92% on RA

  • Supplemental oxygen therapy
1st line: IV naloxone boluses 100-200 mcg every 60 sec (maximum dose: 2,000 mcg)

RR >10 after naloxone = adequate response to naloxone

  • If the patient failed to respond to 2,000 mcg of naloxone → consider alternative diagnoses
  • If the patient initially responded to naloxone but subsequently deterioates:
    • Further IV naloxone boluses up to a maximum of 2,000 mcg
    • Consider naloxone infusion

Consider discharge if RR, SpO2, ETCO2, and level of consciousness are within normal limits 4 hours after naloxone and if it has been 6 hours since time of overdose

Respiratory arrest

OR

RR ≤5/min

OR

SpO2 <85% on RA

Ventilate with BVM
  • 15 L/min of oxygen
  • 10-12 breaths/min
1st line: IV naloxone bolus 400 mcg
  • If no available IV access: IO / IM route

If there is no response after the first dose

  • Repeat naloxone with higher doses
  • If there is lack of response after 3 doses → urgent critical care referral + consider advanced airway support + consider alternative diagnosis

Naloxone = antidote for opioid toxicity / overdose

  • Naloxone is used to 1) reverse respiratory depression and 2) maintain airway protective reflexes
  • However, naloxone does NOT fully reverse the CNS depression

References

Share Your Feedback Below

Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Stay Updated withGuideline Genius

Sign up to be notified when our newsletter launches, covering major guideline updates, article updates, and future UKMLA resources.